Has Opada Alzohaili, MD received payments from drug or device companies?

Yes. Drug and device makers reported $152,067 in general payments to Opada Alzohaili, MD across 595 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Opada Alzohaili, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Opada Alzohaili, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Opada Alzohaili, MD

Endocrinology, Diabetes & Metabolism · Dearborn, MINPI 1912942582

Payments from drug & device makers

$152,067in general payments, 2019–2025

Across 595 payments — averaging $255.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Ascendis Pharma Endocrinology Inc$69K
Rhythm Pharmaceuticals, Inc.$40K
Vertex$11K
Insulet Corporation$6K
Medtronic$5K
Pfizer$4K
plus $18K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Ascendis Pharma Endocrinology Inc	29	$68,636
Rhythm Pharmaceuticals, Inc.	32	$39,773
Vertex	3	$10,724
Insulet Corporation	5	$6,106
Medtronic(2 entities)	31	$5,200
Pfizer	9	$3,714
Sanofi-aventis U.S. LLC	5	$3,614
Novo Nordisk	95	$2,296
Abbott	11	$2,180
Amgen(2 entities)	73	$1,479
Senseonics, Incorporated	36	$866
Lilly USA, LLC	37	$853
Cequr Corporation	6	$521
Mannkind Corporation	7	$451
Bayer	9	$428
AstraZeneca(2 entities)	22	$399
Corcept Therapeutics	7	$339
BD	4	$315
Antares Pharma, Inc.	12	$303
Amarin Pharma, Inc.	11	$239
Pharmacosmos Therapeutics Inc.	2	$231
Daiichi Sankyo Inc.	2	$230
Regeneron Healthcare Solutions, Inc.	6	$224
Radius Health, Inc.	3	$199
Verity Pharmaceuticals Inc.	11	$196
Merck	12	$182
Recordati_rare_diseases_inc.	7	$172
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	5	$148
Sequel Med Tech, LLC	3	$146
Johnson & Johnson	9	$141
Otsuka America Pharmaceutical, Inc.	1	$123
Xeris Pharmaceuticals, Inc.	8	$115
Ascensia Diabetes Care US Inc.	6	$113
Ultragenyx Pharmaceutical Inc.	6	$111
Nevro Corp.	3	$108
Neurocrine Biosciences, Inc.	4	$94
Valeritas, Inc.	1	$85
Dexcom, Inc.	4	$77
Amneal Pharmaceuticals LLC	5	$76
Acella Pharmaceuticals, LLC	4	$71
Novartis	4	$56
Boehringer Ingelheim	3	$55
Tolmar, Inc.	3	$53
Endo Pharmaceuticals Inc.	3	$53
Zealand Pharma US, Inc.	3	$53
Currax Pharmaceuticals LLC	4	$49
Clarus Therapeutics Inc.	3	$48
Acerus Pharmaceuticals Corporation	3	$43
Kyowa Kirin, Inc.	2	$43
Averitas Pharma Inc.	2	$35
Eisai Inc.	2	$32
Shire North American Group Inc	2	$31
Ferring Pharmaceuticals Inc.	2	$26
IBSA Pharma Inc.	2	$26
Amphastar Pharmaceuticals, Inc.	1	$25
Halozyme Inc	1	$21
Astellas Pharma US Inc	1	$20
Ipsen Biopharmaceuticals, Inc	1	$19
Lexicon Pharmaceuticals, Inc.	1	$19
Gilead	1	$16

How this compares

$152,067 in reported general payments places this provider in the 90th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan →

Medicare billing

Part B allowed, 2024

$402,153

Medicare patients

642

Services billed

18,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Dearborn

Mohammad SalehDearborn$19K
Ali AchiraDearborn$9K
Tobias ElseAnn Arbor$3.5M
Elif OralAnn Arbor$2.9M
Jamal HammoudFlint$2.6M
Lowell SchmeltzFarmington Hills$2.3M
George GrunbergerBloomfield Hills$1.9M
Richard AuchusAnn Arbor$1.3M
Ariel BarkanAnn Arbor$553K
Gary EdelsonFarmington Hills$503K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →